The content on this site is intended for healthcare professionals only
Next generation gene sequencing
Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer
Denosumab delayed first skeletal-related side effect
High CTC levels predicted poor outcome in metastatic breast cancer
CTCs predicted recurrence and death in patients with early-stage breast cancer
Combination therapy reduced HER2-positive breast cancers
Neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Cancer therapies that target DNA damage repair
Multidisciplinary approach to breast cancer treatment
World Health Organisation cancer prevention and control
The European Academy of Cancer Sciences
